Publication Name	World Journal of Gastroenterology
Manuscript ID	403
Country	Italy

Received	2012-09-10 18:18
Peer-Review Started	2012-09-11 10:17
To Make the First Decision	2012-09-20 16:06
Return for Revision	2013-01-07 08:16
Revised	2013-01-10 22:51
Second Decision	2013-03-08 16:51
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2013-03-09 06:07
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2013-05-17 20:28
Publish the Manuscript Online	2013-05-28 09:36

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Autobiography
Article Title	Neoadjuvant-intensified treatment for rectal cancer: Time to change?
Manuscript Source	Invited Manuscript
All Author List	Daniela Musio, Francesca De Felice, Nadia Bulzonetti, Roberta Guarnaccia, Rossella Caiazzo, Caterina Bangrazi, Nicola Raffetto and Vincenzo Tombolini
Funding Agency and Grant Number
Corresponding Author	Daniela Musio, MD, Department of Radiotherapy, Policlinico Umberto I University of Rome "Sapienza", Viale Regina Elena 326, 00161 Rome, Italy. daniela.musio@libero.it
Key Words	Rectal cancer; Neoadjuvant treatment; Intensified radiochemotherapy; Oxaliplatin; Fluorouracil
Core Tip	Management of rectal cancer requires a multimodality treatment approach. The objective of this study was to determine whether neoadjuvant-intensified radiochemotherapy, using traditional radiation therapy in combination with oxaliplatin and 5-fluorouracil (5-FU), could improve the overall and disease-free survival rates in patients with locally advanced rectal cancer. Conventional chemotherapeutic strategies typically only use 5-FU infusion. The results from this study indicate that the addition of oxaliplatin to the chemotherapeutic regime enhances the 5-year overall survival rate, facilitates a high rate of sphincter preservation, and reduces the local recurrence rate relative to the traditional strategies previously reported in the literature. Furthermore, oxaliplatin addition was well tolerated by patients, demonstrating an acceptable level of toxicity.
Publish Date	2013-05-28 09:36
Citation	Musio D, De Felice F, Bulzonetti N, Guarnaccia R, Caiazzo R, Bangrazi C, Raffetto N, Tombolini V. Neoadjuvant-intensified treatment for rectal cancer: Time to change? World J Gastroenterol 2013; 19(20): 3052-3061
URL	http://www.wjgnet.com/1007-9327/full/v19/i20/3052.htm
DOI	http://dx.doi.org/10.3748/wjg.v19.i20.3052

Full Article (PDF)	WJG-19-3052.pdf
Manuscript File	403-Review.docx
Answering Reviewers	403-Answering reviewers.doc
Copyright License Agreement	403-Copyright assignment.doc
Non-Native Speakers of English Editing Certificate	403-Language certificate.pdf
Peer-review Report	403-Peer review(s).docx
Scientific Editor Work List	403-Scientific editor work list.doc